GlassScriptPhysician profile
Jennifer Booth
NPI 1003540188
$8,060.96
in general payments reported to CMS, 2019-2025
26 companies · $3,479 in 2025
The $3,479 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $505 · 2024: $4,077 · 2025: $3,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,350 · Education: $445 · Consulting Fee: $250 · Travel and Lodging: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,350.45 |
| Education | $445.09 |
| Consulting Fee | $250.00 |
| Travel and Lodging | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,388.79 | 2024-2025 | |
| Janssen Biotech, INC. | $928.77 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $888.45 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $707.66 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $665.54 | 2023-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $640.01 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $566.57 | 2024-2025 | |
| Dermavant Sciences, INC. | $388.88 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $299.22 | 2024-2025 | |
| Lilly USA, LLC | $287.88 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2025 | Neo-Synalar |
| Galderma Laboratories, L.P. | $239.46 | 2024-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $189.36 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $117.40 | 2024-2025 | |
| Amgen INC. | $71.57 | 2024 | Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $67.40 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.28 | 2024 | Cabtreo, Duobrii, Siliq |
| Organon LLC | $53.80 | 2025 | Vtama |
| Lnhc, INC | $42.09 | 2025 | Zelsuvmi |
| Botanix Sb INC | $41.49 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $34.43 | 2025 | Spinosad, Natroba |
| Smith+Nephew, INC. | $30.36 | 2024-2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $27.17 | 2024-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.55 | 2025 | Spevigo |
| Almirall LLC | $21.92 | 2024 | Klisyri |
| Pfizer INC. | $19.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.